Vanda Pharmaceuticals (VNDA) Receivables - Other (2011 - 2012)
Vanda Pharmaceuticals (VNDA) posted Receivables - Other of $21000.0 for Q3 2012, down 19.23% sequentially from $26000.0 in Q2 2012.
Powered by 
Analysis
Vanda Pharmaceuticals (VNDA) Receivables - Other (2011 - 2012) Analysis & Trends
Vanda Pharmaceuticals has reported Receivables - Other for 2 years, with the latest figure at $21000.0 in Q3 2012.
- Quarterly Receivables - Other changed N/A year-over-year to $21000.0 in Q3 2012, while the trailing twelve-month figure through Sep 2012 was $21000.0 (changed N/A YoY) and the FY2011 annual result came in at $116000.0, changed N/A from the prior year.
- Receivables - Other fell to $21000.0 in Q3 2012 per VNDA's latest filing, from $26000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $116000.0 in Q4 2011 and troughed at $21000.0 in Q3 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Vanda Pharmaceuticals | 327.03 Mn | 157.00 Mn | 46.97 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2012 | 21,000.00 |
| Jun 30, 2012 | 26,000.00 |
| Dec 31, 2011 | 116,000.00 |